SEC Form 4 · accession 0001209191-17-022772
EAGLE PHARMACEUTICALS, INC. · EGRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Steven L. Krill
Officer — EVP & Chief Scientific Officer
Period of report
Mar 22, 2017
Accepted (ET)
Mar 24, 2017 · 4:41 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000827871
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 22, 2017 | M | 5,023 | $4.42 | A | 5,023 | D | |
| Common Stock | Mar 22, 2017 | M | 2,077 | $12.67 | A | 7,100 | D | |
| Common Stock | Mar 22, 2017 | S | 7,100 | $80.0903 | D | 0 | D | |
| Common Stock | Mar 23, 2017 | M | 2,025 | $12.67 | A | 2,025 | D | |
| Common Stock | Mar 23, 2017 | M | 5,000 | $12.63 | A | 7,025 | D | |
| Common Stock | Mar 23, 2017 | S | 7,025 | $82.0625 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $4.42 | Mar 22, 2017 | M | 5,023 | D | — | Apr 18, 2023 | Common Stock | 5,023 | 457 | D |
| Employee Stock Option (right to buy)F2 | $12.67 | Mar 22, 2017 | M | 2,077 | D | — | Apr 7, 2024 | Common Stock | 2,077 | 6,875 | D |
| Employee Stock Option (right to buy)F2 | $12.67 | Mar 23, 2017 | M | 2,025 | D | — | Apr 7, 2024 | Common Stock | 2,025 | 4,850 | D |
| Employee Stock Option (right to buy)F3 | $12.63 | Mar 23, 2017 | M | 5,000 | D | — | Aug 25, 2024 | Common Stock | 5,000 | 15,000 | D |
Explanation of responses
- F125% of the shares subject to the option vested on April 19, 2014 and the remainder shall vest in equal monthly installments over a period of three years.
- F225% of the shares subject to the option vested on April 8, 2015 and the remainder shall vest in equal monthly installments over a period of three years.
- F325% of the shares subject to the option vested on August 26, 2015 and the remainder shall vest in equal monthly installments over a period of three years.